title: High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
abstract: The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy.
authors.affiliation: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
authors.forename: Maryam
authors.initials: M
authors.lastname: Pourabdollah
authors.affiliation: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Bahmanyar
authors.affiliation: Department of Biostatistics, University of Toronto, Toronto, Canada.
authors.forename: Eshetu G
authors.initials: EG
authors.lastname: Atenafu
authors.affiliation: Department of Hematology and Medical Oncology, University of Toronto, Toronto, Canada.
authors.forename: Donna
authors.initials: D
authors.lastname: Reece
authors.affiliation: Department of Hematology, Shanghai Chang Zheng Hospital, Shanghai, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
authors.affiliation: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. hong.chang@uhn.ca.|Department of Laboratory Hematology, University Health Network, 200 Elizabeth Street, 11E-413, Toronto, ON, M5G 2C4, Canada. hong.chang@uhn.ca.
authors.forename: Hong
authors.initials: H
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D051740:Ikaros Transcription Factor / Q000032:analysis*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C497239:IKZF1 protein, human; C106285:IKZF3 protein, human; D051740:Ikaros Transcription Factor; D013792:Thalidomide; D000077269:Lenalidomide